Precision Oncology Trends
The latest news on precision oncology research trends.
The company has collected initial evidence for an algorithmic method to predict immunotherapy response, and is studying its technology in treatment monitoring.
The firm hopes to return fewer VUS in its test reports and to accelerate the resolution of uncertain results issued to patients in that past.
A collection of biomarker- and genomic testing-driven precision oncology research presented at the European Society of Medical Oncology Congress.
Whether they're analyzing checkpoint inhibitors, CAR T cells, or combination regimens, pediatric cancer researchers must carefully consider which targets and drugs to trial.
The company said it has seen progress in efforts to get FDA approval for its tissue and liquid biopsy tests as data continues to accumulate for pan-cancer utility.
Funded projects will look at the combination of imaging and liquid biopsies for monitoring cancer patient responses and the emergence of treatment resistance.
The researchers aimed to develop a test that could help clinicians determine whether a patient would respond to therapy, before the onset of treatment.
The company believes the multi-omic approach it has honed for early cancer detection can also glean predictive signatures of drug response from both tumor and immune signals.
Researchers studied isolated CTCs along with real-world patient data and found that patients with blood-borne HER2 mutations may respond to anti-HER2 treatment.
The company said it is on track to complete a clinical validation by the end of next year, after which it would launch its assay for clinical use.